CC-chemokine receptor 7 is overexpressed and correlates with growth and metastasis in prostate cancer
- PMID: 25682287
- DOI: 10.1007/s13277-015-3222-8
CC-chemokine receptor 7 is overexpressed and correlates with growth and metastasis in prostate cancer
Retraction in
-
Retraction Note to multiple articles in Tumor Biology.Tumour Biol. 2017 Apr 20. doi: 10.1007/s13277-017-5487-6. Online ahead of print. Tumour Biol. 2017. PMID: 28792236 No abstract available.
Abstract
Multiple studies have shown that CC-chemokine receptor 7 (CCR7) promotes cell proliferation in several human cancers. We investigated the expression and clinical significance of CCR7 in our large collection of prostate cancer (PCa) samples and explored its function on the proliferation and migration of PCa cells. In this study, the expression of CCR7 was examined by immunohistochemical staining and quantitative RT-PCR in primary PCa tissues from 60 patients who underwent radical prostatectomy. Then, we investigated the functional role of CCR7 in PCa cell proliferation and migration by small interfering RNA-mediated depletion. The positive rate of CCR7 staining was 88.33 % (53/60) in the PCa group and 16.67 % (10/60) in cases of benign prostate hyperplasia (BPH); the difference of CCR7 expression between PCa and BPH was statistically significant. The results were confirmed by quantitative real-time PCR. CCR7 was significantly elevated in all five PCa cell lines when compared to the RWPE-1 cells. Silencing of CCR7 inhibited the proliferation of PC3 cells which have a relatively high level of CCR7 in a time-dependent manner, and the invasion and migration of PC3 cells were distinctly suppressed. Our data suggest that the pathogenesis of human PCa maybe mediated by the CCR7, and thus CCR7 could represent selective targets for the molecularly targeted treatments of PCa.
Similar articles
-
The effect of CCL19/CCR7 on the proliferation and migration of cell in prostate cancer.Tumour Biol. 2015 Jan;36(1):329-35. doi: 10.1007/s13277-014-2642-1. Epub 2014 Sep 26. Tumour Biol. 2015. Retraction in: Tumour Biol. 2017 Apr 20. doi: 10.1007/s13277-017-5487-6. PMID: 25256673 Retracted.
-
CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.Tumour Biol. 2015 Jun;36(6):4777-83. doi: 10.1007/s13277-015-3129-4. Epub 2015 Jan 31. Tumour Biol. 2015. Retraction in: Tumour Biol. 2017 Apr 20. doi: 10.1007/s13277-017-5487-6. PMID: 25636449 Retracted.
-
CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.Tumour Biol. 2015 May;36(5):3583-9. doi: 10.1007/s13277-014-2995-5. Epub 2015 Jan 6. Tumour Biol. 2015. Retraction in: Tumour Biol. 2017 Apr 20. doi: 10.1007/s13277-017-5487-6. PMID: 25560487 Retracted.
-
The role of tumor suppressor gene SOX11 in prostate cancer.Tumour Biol. 2015 Aug;36(8):6133-8. doi: 10.1007/s13277-015-3296-3. Epub 2015 Mar 14. Tumour Biol. 2015. PMID: 25773392
-
Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12533-40. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26722441 Free PMC article.
Cited by
-
CCR7 Maintains Nonresolving Lymph Node and Adipose Inflammation in Obesity.Diabetes. 2016 Aug;65(8):2268-81. doi: 10.2337/db15-1689. Epub 2016 May 3. Diabetes. 2016. PMID: 27207557 Free PMC article.
-
Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.Onco Targets Ther. 2015 Jul 30;8:1915-22. doi: 10.2147/OTT.S86637. eCollection 2015. Onco Targets Ther. 2015. PMID: 26261420 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical